Tagged with RNA

Pharma Jean-Charles Foddis, executive director of Aderly, Lyon’s main investment agency, discusses the city’s history of economic development while highlighting its main strengths and challenges for the future in life sciences. You came to Aderly in August 2015, having previously worked in a number of different positions predominantly in life sciences.…

Pharma Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director  Bernat Albinyana discusses the affiliate’s performance, its business organization and commitment to R&D, as well as its grand ambitions for the next few years. In 1986, Italy was…

Pharma Arnaud Pradel, Product Development Director and Co-Segment Leader of HORIBA Medical reveals how HORIBA has over 30 years of experience when it comes to launching products in the vitro diagnostic space, and in managing distributors in over 130 countries; why historically there has been a close relationship between the global…

Pharma Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape of immunotherapy as well as the evolution of the French biotech environment, and finally, their mission to position Effimune as…

Pharma Alessandra Modenese Kauffmann, General Manager of the Swiss Chamber of Commerce, shares her insights into the relationship between Italy and Switzerland, the Chamber’s efforts to foster trade between the two countries and the opportunities offered through close collaboration between Swiss and Italian companies. Alessandra, the chamber has been active in…

Pharma The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported, primarily to emerging countries, and why there is a very hopeful future for medium-sized companies that are ready to embrace…

pharma   Mitel Distributing Corp is one of Puerto Rico’s leading distributors for weights and scales in the life science industry. The executive team speaks about the challenges of Puerto Rico’s recession and ways that the company has adapted as a result. What have been the biggest opportunities and challenges over…

Pharma The managing director of MC Pharma Group, Henk Krebs illustrates how MC Pharma’s new operating structure enables the group to better service its clients, and also highlights the role of strategic partnerships in fueling the company’s growth ambitions both domestically and internationally. He also shares his insights on the South…

France The President and the Counselor of the French Chamber of Commerce and Industry in Egypt, discuss plans to establish a French industrial zone in Alexandria (North of Egypt) to further attract French FDI, and furthermore highlight the unique French-Egyptian relationship. Could you please introduce us to the French-Egyptian relationship? Mahmoud…

Pharma Juan Sénquiz, President and CEO of JC Automation, weighs in on the capacity of Puerto Rico’s local pharma service industry to grow globally and how the company’s computerized systems services have helped some of the biggest names in the industry to automate more effectively. We have seen a lot of…

women's health Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets.   The crisis has changed the way companies operate in Spain, but Chemo has continued to succeed. What have been some of the key strategies employed? It has been a…

Internationalization José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and development in total, Zeltia was finally able to commercialize a novel product.  Would you say that this investment was worth…